These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 30397837)

  • 1. Implications of the CANVAS Study in Reducing Cardiovascular Outcomes.
    Madan Paramasivan A; Purushothaman A; Desouza C
    Curr Diab Rep; 2018 Nov; 18(12):142. PubMed ID: 30397837
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic modelling of costs associated with outcomes reported for type 2 diabetes mellitus (T2DM) patients in the CANVAS and EMPA-REG cardiovascular outcomes trials.
    Kamstra R; Durkin M; Cai J; Bookhart B; Lafeuille MH; Pilon D; Tiggelaar S; Manceur AM; Lefebvre P
    J Med Econ; 2019 Mar; 22(3):280-287. PubMed ID: 30575426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. SGLT2 Inhibitors Through the Windows of EMPA-REG and CANVAS Trials: A Review.
    Rastogi A; Bhansali A
    Diabetes Ther; 2017 Dec; 8(6):1245-1251. PubMed ID: 29076040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.
    Perkovic V; de Zeeuw D; Mahaffey KW; Fulcher G; Erondu N; Shaw W; Barrett TD; Weidner-Wells M; Deng H; Matthews DR; Neal B
    Lancet Diabetes Endocrinol; 2018 Sep; 6(9):691-704. PubMed ID: 29937267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renoprotective effects of sodium-glucose cotransporter-2 inhibitors.
    Heerspink HJL; Kosiborod M; Inzucchi SE; Cherney DZI
    Kidney Int; 2018 Jul; 94(1):26-39. PubMed ID: 29735306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cardiorenal protection with SGLT2 inhibitors (gliflozins) : from EMPA-REG OUTCOME to CANVAS].
    Scheen AJ; Ernest P; Jandrain B
    Rev Med Suisse; 2017 Aug; 13(571):1421-1426. PubMed ID: 28837279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. External applicability of SGLT2 inhibitor cardiovascular outcome trials to patients with type 2 diabetes and cardiovascular disease.
    Smidt LCA; Visseren FLJ; de Ranitz-Greven WL; Nathoe HM; Kappelle LJ; de Borst GJ; de Valk HW; Westerink J;
    Cardiovasc Diabetol; 2021 Sep; 20(1):181. PubMed ID: 34496847
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eligibility of patients with type 2 diabetes for sodium-glucose cotransporter 2 inhibitor cardiovascular outcomes trials: a global perspective from the DISCOVER study.
    Pintat S; Fenici P; Hammar N; Ji L; Khunti K; Medina J; Tang F; Wittbrodt E; Surmont F
    BMJ Open Diabetes Res Care; 2019; 7(1):e000627. PubMed ID: 31114700
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials.
    Yu J; Zhou Z; Mahaffey KW; Matthews DR; Neuen BL; Heerspink HJL; Jardine MJ; Li J; Perkovic V; Neal B; Arnott C
    Int J Cardiol; 2021 Feb; 324():165-172. PubMed ID: 32979427
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on SGLT2 Inhibitors-New Data Released at the American Diabetes Association.
    Lee S
    Crit Pathw Cardiol; 2017 Sep; 16(3):93-95. PubMed ID: 28742644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The kidney and cardiovascular outcome trials.
    Bloomgarden Z
    J Diabetes; 2018 Feb; 10(2):88-89. PubMed ID: 29031006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lower Risk of Death With SGLT2 Inhibitors in Observational Studies: Real or Bias?
    Suissa S
    Diabetes Care; 2018 Jan; 41(1):6-10. PubMed ID: 29263192
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program.
    Zhou Z; Jardine M; Perkovic V; Matthews DR; Mahaffey KW; de Zeeuw D; Fulcher G; Desai M; Oh R; Simpson R; Watts NB; Neal B
    Diabetologia; 2019 Oct; 62(10):1854-1867. PubMed ID: 31399845
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluating the Ability of Economic Models of Diabetes to Simulate New Cardiovascular Outcomes Trials: A Report on the Ninth Mount Hood Diabetes Challenge.
    Si L; Willis MS; Asseburg C; Nilsson A; Tew M; Clarke PM; Lamotte M; Ramos M; Shao H; Shi L; Zhang P; McEwan P; Ye W; Herman WH; Kuo S; Isaman DJ; Schramm W; Sailer F; Brennan A; Pollard D; Smolen HJ; Leal J; Gray A; Patel R; Feenstra T; Palmer AJ
    Value Health; 2020 Sep; 23(9):1163-1170. PubMed ID: 32940234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of canagliflozin on major adverse cardiovascular events by baseline estimated glomerular filtration rate: Pooled Hispanic subgroup analyses from the CANVAS Program and CREDENCE trial.
    Weir MR; Gogate J; Damaraju CV; Correa-Rotter R; Mahaffey KW
    Diabetes Obes Metab; 2022 Jan; 24(1):12-20. PubMed ID: 34463423
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Canagliflozin for Primary and Secondary Prevention of Cardiovascular Events: Results From the CANVAS Program (Canagliflozin Cardiovascular Assessment Study).
    Mahaffey KW; Neal B; Perkovic V; de Zeeuw D; Fulcher G; Erondu N; Shaw W; Fabbrini E; Sun T; Li Q; Desai M; Matthews DR;
    Circulation; 2018 Jan; 137(4):323-334. PubMed ID: 29133604
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program.
    Yu J; Arnott C; Neuen BL; Heersprink HL; Mahaffey KW; Cannon CP; Khan SS; Baldridge AS; Shah SJ; Huang Y; Li C; Figtree GA; Perkovic V; Jardine MJ; Neal B; Huffman MD
    ESC Heart Fail; 2021 Apr; 8(2):1482-1493. PubMed ID: 33595905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular outcome studies in type 2 diabetes: Comparison between SGLT2 inhibitors and GLP-1 receptor agonists.
    Scheen AJ
    Diabetes Res Clin Pract; 2018 Sep; 143():88-100. PubMed ID: 29944969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-Organ Protective Effects of Sodium Glucose Cotransporter 2 Inhibitors.
    Yanai H; Hakoshima M; Adachi H; Katsuyama H
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33922546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.